Yue Wu Net Worth

The estimated Net Worth of Yue Alexander Wu is at least $301 millier dollars as of 3 February 2017. Yue Wu owns over 5,000 units of Sorrento Therapeutics Inc stock worth over $50 and over the last 8 years he sold SRNE stock worth over $0. In addition, he makes $301,400 as Independent Director at Sorrento Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Yue Wu SRNE stock SEC Form 4 insiders trading

Yue has made over 1 trades of the Sorrento Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 5,000 units of SRNE stock worth $25,750 on 3 February 2017.

The largest trade he's ever made was buying 5,000 units of Sorrento Therapeutics Inc stock on 3 February 2017 worth over $25,750. On average, Yue trades about 500 units every 0 days since 2017. As of 3 February 2017 he still owns at least 5,000 units of Sorrento Therapeutics Inc stock.

You can see the complete history of Yue Wu stock trades at the bottom of the page.

Yue Wu biography

Dr. Yue Wu Ph.D. serves as Independent Director of the Company. Dr. Wu is currently an advisor to Crown Bioscience International. He was previously President, Chief Executive Officer and Chief Scientific Officer of Crown Bioscience International, a leading global drug discovery and development solutions company, which he co-founded in 2006, until 2017. From 2004 to 2006, Dr. Wu was Chief Business Officer of Starvax International Inc. in Beijing, China, a biotechnology company focusing on oncology and infectious diseases. From 2001 to 2004, Dr. Wu was a banker with Burrill & Company where he was head of Asian Activities. Dr. Wu has served as a director of CASI Pharmaceuticals, Inc. since June 2013. Dr. Wu received his Ph.D. in Molecular Cell Biology and his MBA from University of California at Berkeley. He earned an M.S. in Biochemistry from University of Illinois, Urbana-Champaign and his B.S. in Biochemistry from Fudan University in Shanghai, China.

What is the salary of Yue Wu?

As the Independent Director of Sorrento Therapeutics Inc, the total compensation of Yue Wu at Sorrento Therapeutics Inc is $301,400. There are 5 executives at Sorrento Therapeutics Inc getting paid more, with Jaisim Shah having the highest compensation of $10,971,100.

How old is Yue Wu?

Yue Wu is 56, he's been the Independent Director of Sorrento Therapeutics Inc since 2017. There are 7 older and 4 younger executives at Sorrento Therapeutics Inc. The oldest executive at Sorrento Therapeutics Inc is Dr. Michael A. Royal, 67, who is the SVP & Chief Medical Officer.

What's Yue Wu's mailing address?

Yue's mailing address filed with the SEC is CASI PHARMACEUTICALS, INC., 9620 MEDICAL CENTER DR. SUITE 300, ROCKVILLE, MD, 20850.

Insiders trading at Sorrento Therapeutics Inc

Over the last 15 years, insiders at Sorrento Therapeutics Inc have traded over $17,198,839 worth of Sorrento Therapeutics Inc stock and bought 10,353,437 units worth $10,703,222 . The most active insiders traders include Jane Ph D Hsiao, Edgar Lee et Patrick Chan Soon Shiong Fa.... On average, Sorrento Therapeutics Inc executives and independent directors trade stock every 60 days with the average trade being worth of $2,947. The most recent stock trade was executed by Henry Ji on 7 September 2022, trading 88,888 units of SRNE stock currently worth $179,554.

What does Sorrento Therapeutics Inc do?

sorrento therapeutics is an antibody-centric, clinical stage biopharmaceutical company developing new treatments for cancer, inflammation and autoimmune diseases. sorrento's lead products are multiple late-stage biosimilar and biobetter antibodies, as well as clinical car-t therapies targeting solid tumors.

Complete history of Yue Wu stock trades at CASI Pharmaceuticals Inc et Sorrento Therapeutics Inc

Sorrento Therapeutics Inc executives and stock owners

Sorrento Therapeutics Inc executives and other stock owners filed with the SEC include:

• Jaisim Shah,
  Director
• Henry Ji,
  Chairman of the Board, President, Chief Executive Officer, Co-Founder
• Dr. Henry H. Ji Ph.D.,
  Chairman, Pres & CEO
• Najjam Asghar,
  Sr. VP & CFO
• Kim Janda,
  Director
• Yue Wu,
  Independent Director
• Dorman Followwill,
  Lead Independent Director
• David Lemus,
  Independent Director
• Robin Smith,
  Independent Director
• Edgar Lee,
  Independent Director
• Najjam Asghar,
  Chief Financial Officer
• William J. Farley,
  VP of Sales & Bus. Devel.
• Dr. Robert D. Allen Ph.D.,
  Sr. VP of Antiviral & Immunotherapy
• Brian Cooley,
  Sr. VP of Lymphatic Drug Delivery BU Leader
• Dr. Shawn Sahebi Ph.D.,
  Sr. VP of Strategy & Analytics
• Dr. Mark R. Brunswick,
  Sr. VP of Regulatory Affairs
• Dr. Alexis Nahama,
  Sr. VP & Head of RTX Program
• Dr. Michael A. Royal,
  SVP & Chief Medical Officer
• Bill Farley,
  VP of Sales & Bus. Devel.
• Brian Sun,
  Sr. VP, Gen. Counsel & Corp. Sec.
• Jane Ph D Hsiao,
  Director
• Management Ltd Abg Srne Ltd...,
  
• Douglas O Ebersole,
  Director
• Jeffrey Su,
  Executive VP and COO
• Kevin Herde,
  Executive VP and CFO
• William S Marth,
  Director
• Management Ltd Abg Srne Ltd...,
  
• George K Ng,
  See Remarks
• Patrick Chan Soon Shiong Fa...,
  
• Jerome B Zeldis,
  See Remarks
• David H Deming,
  Director
• Antonius Schuh,
  Chairman and CEO
• Steve Zaniboni,
  Director
• Curtis Lockshin,
  Director
• Donald R Scifres,
  10% owner
• Diane D S Tang Liu,
  Director
• Glenn L Halpryn,
  Director
• Charles P Rodi,
  VP, Research & Development
• Martina Molsbergen,
  VP, Business Development
• Dean Ferrigno,
  Chief Accounting Officer
• Pacific Med Tech (Bvi) Ltd ...,
  
• Management Ltd Abg Srne Ltd...,
  
• Management Ltd Abg Ii So Lt...,
  
• Jiong Shao,
  Chief Financial Officer
• Zhenwei Miao,
  Chief Technology Officer
• George Uy,
  Chief Commercial Officer
• Patrickmp 13 Ventures, Llc ...,
  
• Michael Scott Salka,
  Director
• Health, Inc. Opko,
  10% owner
• Mark Durand,
  Director
• Richard G Vincent,
  Chief Financial Officer
• Cam Gallagher,
  Director
• David Ritchie Webb,
  Director
• Ernst Guenter Afting,
  Director
• Vuong Trieu,
  CSO
• Elizabeth Czerepak,
  EVP & Chief Financial Officer
• Tammy Reilly,
  Director